Document Detail

The role of HBsAg quantification for monitoring natural history and treatment outcome.
MedLine Citation:
PMID:  23286856     Owner:  NLM     Status:  In-Data-Review    
Since its discovery by Blumberg in 1965, the hepatitis B virus antigen (HBsAg) is used as the fingerprint of hepatitis B infection. The HBsAg level is a reflection of the transcriptional activity of cccDNA. It is an important marker that not only indicates active hepatitis B infection but can also predict clinical and treatment outcomes. Assays for HBsAg quantification are fully automated and have high output. HBsAg titres are higher in HBe antigen (HBeAg)(+) than in HBeAg(-) patients and are negatively correlated with liver fibrosis in HBeAg(+) patients. In HBeAg(-) chronic hepatitis B, an HBsAg level <1000 IU/ml and an HBV DNA titre <2000 IU/ml accurately identify inactive carriers. During PEG-IFN treatment, HBsAg quantification is used to identify patients who will not benefit from therapy as early as week 12 on therapy, so that treatment may be stopped or switched- 'week 12 stopping rule'. With nucleos(t)ide analogues (NA), the role of HBsAg quantification must be clarified. Several studies show that baseline and on-treatment HBsAg levels might identify patients that can be treated with no subsequent risk of reactivation. In clinical practice, HBsAg quantification is a simple and reproducible tool that can be used in association with HBV DNA to classify patients during the natural history of HBV and to monitor therapy.
Michelle Martinot-Peignoux; Martine Lapalus; Tarik Asselah; Patrick Marcellin
Related Documents :
24967226 - Evaluation of an isolation program of hepatitis c virus infected hemodialysis patients ...
24812506 - Nanomedicines in the treatment of hepatitis c virus infection in asian patients: optimi...
438796 - The frequency and identification of false positive conversion reactions.
25135516 - Hiv and aids in poland in 2012.
18405126 - Hiv sero-prevalance in general population of warangal, a.p., south india.
16470116 - Hepatic steatosis in hiv-hcv coinfected patients: analysis of risk factors.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  33 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  125-32     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons A/S.
INSERM, U-773, CRB3, Université Paris-Diderot, Hôpital Beaujon, Clichy, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resista...
Next Document:  Why do I treat HBeAg-positive chronic hepatitis B patients with a Nucleoside analogue.